Announcements Trials
Browse Landscape

Status

Completed 4

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 29Observational 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 4Prostatic Hyperplasia 2Neoplasms 1

Interventions

Surveys and Questionnaires 52Blood Specimen Collection 47enzalutamide 29radium Ra 223 dichloride 22Biopsy 20darolutamide 19Radiotherapy 19Docetaxel 19apalutamide 18Sunitinib 18Magnetic Resonance Spectroscopy 18Sorafenib 17Abiraterone Acetate 17Watchful Waiting 16Interviews as Topic 15Gene Expression Profiling 15Amplified Fragment Length Polymorphism Analysis 15Observation 13Leuprolide 13Immunohistochemistry 13Androgen Antagonists 13acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 12Magnetic Resonance Imaging 12avelumab 11Specimen Handling 11abiraterone 9Polymerase Chain Reaction 9Flow Cytometry 9Radiosurgery 8Microarray Analysis 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Observational × Dutasteride × Genitourinary × Clear all
NCT01594502 2020-10-12

Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies

University of Illinois at Chicago

Completed
139 enrolled
Genitourinary

Prostatic Neoplasms

NCT00883909 2017-07-11

ARI103094-Follow-Up Study for REDUCE Study Subjects

GlaxoSmithKline

Completed
2,795 enrolled
Genitourinary

Prostatic Hyperplasia, Prostatic Neoplasms

NCT01337258 2017-05-30

Economic Analyses of the REDUCE Trial

GlaxoSmithKline

Completed
1 enrolled
Genitourinary

Neoplasms, Prostatic Hyperplasia, Prostatic Neoplasms

NCT01525914 2012-02-03

Response of Patients on Surveillance for Prostate Cancer to Dutasteride

Sunnybrook Health Sciences Centre

Completed
100 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡